A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.
|ClinicalTrials.gov Identifier: NCT00269971|
Recruitment Status : Withdrawn
First Posted : December 26, 2005
Last Update Posted : September 20, 2016
|Condition or disease||Intervention/treatment||Phase|
|Anemia Blood Transfusion Orthopedic Surgery||Drug: epoetin alfa||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Parallel Group Placebo-Controlled Study to Determine an Effective Dose Regimen for EPREX� (Epoetin Alfa) Sterile Solution to Reduce Transfusion Requirements in Patients Undergoing Major Elective Orthopedic Surgery|
|Study Start Date :||May 1996|
|Study Completion Date :||April 1999|
- Transfusion requirements at the time of surgery; hemoglobin and hematocrit levels, reticulocyte count, and iron stores prior to surgery; time to hospital discharge after surgery, and the patient's quality of life after surgery.
- Deep-vein blood clots; other adverse events, changes in clinical laboratory tests, vital sign measurements, and physical examination findings.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00269971
|Study Director:||Janssen-Ortho Inc. Clinical Trial||Janssen-Ortho Inc., Canada|